| 
Tropine 3 ("Homatropine") is the novel new indication that Eaton recently acquired the Assigned rights to the Patent Pending application United States Office of Patent & Trademark No. 60/719,756.
Tropine 3 is an orally ingested prescription product containing Homotropine that is intended to reduce climacteric symptoms and improve quality of life in menopausal women not receiving HRT (women who are experiencing "hot flashes" and "night sweats").
Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that inhibit muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic to temporarily paralyze accommodation, and as a mydriatic, to dilate the pupil.
For Homatropine methylbromide Methylhomatropine, this is a different medication. Homatropine is less potent than atropine and has a shorter duration of action. It is available as the hydrobromide salt. | |  At Eaton Scientific we create
solutions for a better tomorrow.
|
| | | | Today's Mature Woman  Put the burdens of menoppause to rest.
Night sweats or sleep hyperhidrosis are conditions in which the body's temperature monitoring system goes awry during menopause. In fact more than 75% of women can experience NIGHT SWEATS, the night time HOT FLASH. Eaton Scientific's TROPINE 3 has been tested sussessfully on patients suffering from sleep hyperhidrosis. | | 
Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic (anti-AChase) administration. Homatropine is an anti-muscarinic which acts on the eye muscles to produce dilatation of the pupil (mydriasis), and prevents the eye from accommodating for near vision (cyclopegia). This substance is typically used by an optometrist or ophthalmologist, to facilitate examination of the inside of a patient's eye.
About Eaton Scientific Systems, Ltd. Eaton Scientific Systems, Ltd. ("Eaton") was founded in January 2006 in Los Angeles, CA and headquartered in Beverly Hills California with the mandate to develop, license and seek U.S. and International regulatory approvals of its drugs and treatments targeting womens health.
Eaton's acquisition of a novel indication of Homatropine, is currently patent pending with the United States Patent and Trademark Office. Our novel indication is for an oral suspension of Homatropine prescribed to target climeratic conditions known as "Hot Flashes". The Company has named the new indication of Homatropine "Tropine 3". Tropine 3 is an orally ingested prescription product containing Homatropine that is intended to reduce climacteric symptoms and improve quality of life in menopausal women not receiving HRT (women who are experiencing "hot flashes" and "night sweats"). To date, doctors in Los Angeles, CA have prescribed a compound version of Tropine 3 to their patients who are experiencing hot flashes.  Homatropine, an ingredient in a Food and Drug Administration ("F.D.A.") approved prescription anti-tussive (capable of relieving or suppressing coughing), was isolated by Rox-San Pharmacy, located in Beverly Hills, California. The Company has retained a team of accredited medical professionals and is presently drafting the final elements of its Protocol in order to obtain FDA approval to commence a Clinical Trial (the "Trial"). The purpose of the clinical trial will be to obtain the regulatory approval of Tropine 3 by the Food & Drug Administration ("F.D.A."). The Trial will look at the specificity and efficacy of the drug Homatropine in an oral suspension to see if it will provide relief of hot flashes and night sweats and improve the quality of life in women dealing with hot flashes or experiencing menopausal symptoms.  Homatropine has almost 40 years of visibility and is already a generic drug; therefore the trial will not be looking at toxicity which is almost always a main reason for a drugs delay in obtaining a regulatory approval. The Company anticipates that the Study will be completed, barring any unforeseen delays, some time during the 2nd calendar quarter of 2013.
The Clinical Trial will be a Phase 2-3, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Parallel-Group-Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving HRT.
Try reading the SEC filings for accurate information:
http://www.sec.gov/cgi-bin/browse-edgar?company=pristine+solutions&match=&CIK=&filenum=&State=&Country=&SIC=&owner=include&Find=Find+Companies&action=getcompany | 